Harrow reports that it has executed a 5-year strategic supply and development (SSD) agreement for Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that is approved by the US Food and Drug Administration (FDA) for visualization during vitrectomy and the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. 

The SSD agreement is with the current contract manufacturing organization producing Triesence, ensuring continuity in quality and leveraging more than 15 years of experience with the Triesence manufacturing process, Harrow said in a press release. In addition, the company announced that it has begun developing a next-generation version of Triesence and plans to submit a new drug application to the FDA before the end of 2027.

Triesence had been unavailable for 2 years in the United States, and on the FDA's Drug Shortage List for more than 5 years, before Harrow restarted production last year. 

Triesence has a dedicated HCPCS J code, J3300, for use when billing. RP